Checkpoint Therapeutics Inc (NASDAQ:CKPT)’s traded shares stood at 0.59 million during the last session, with the company’s beta value hitting 1.37. At the close of trading, the stock’s price was $3.18, to imply a decrease of -4.50% or -$0.15 in intraday trading. The CKPT share’s 52-week high remains $4.50, putting it -41.51% down since that peak but still an impressive 56.6% since price per share fell to its 52-week low of $1.38. The company has a valuation of $155.29M, with an average of 0.86 million shares in intraday trading volume over the past 10 days and average of 1.47 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Checkpoint Therapeutics Inc (CKPT), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give CKPT a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.12.
Checkpoint Therapeutics Inc (NASDAQ:CKPT) trade information
After registering a -4.50% downside in the last session, Checkpoint Therapeutics Inc (CKPT) has traded red over the past five days. The 5-day price performance for the stock is 0.63%, and -6.19% over 30 days. With these gigs, the year-to-date price performance is -0.62%. Short interest in Checkpoint Therapeutics Inc (NASDAQ:CKPT) saw shorts transact 5.56 million shares and set a 5.7 days time to cover.
Checkpoint Therapeutics Inc (CKPT) estimates and forecasts
Looking at statistics comparing Checkpoint Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Checkpoint Therapeutics Inc (CKPT) shares are 23.50% up over the last 6 months, with its year-to-date growth rate higher than industry average at 71.29% against 16.60%. The rating firms project that company’s revenue will shrink -72.57% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is 10.33k. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 4.53M.
CKPT Dividends
Checkpoint Therapeutics Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Checkpoint Therapeutics Inc (NASDAQ:CKPT)’s Major holders
Checkpoint Therapeutics Inc insiders hold 15.52% of total outstanding shares, with institutional holders owning 13.91% of the shares at 16.47% float percentage. In total, 13.91% institutions holds shares in the company.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Checkpoint Therapeutics Inc (CKPT) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 1.09 shares. This is just over 2.27% of the total shares, with a market valuation of $3.48 million. Data from the same date shows that the other fund manager holds a little less at 265.74, or 0.55% of the shares, all valued at about 0.85 million.
